Spero Therapeutics

123 articles with Spero Therapeutics

• Spero Therapeutics to Present Data at IDWeek 2021

  9/16/2021

  Spero Therapeutics, Inc. today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeek TM 2021, taking place virtually from September 29 – October 3, 2021.

• Spero Therapeutics to Present at Three Upcoming Investor Conferences

  9/7/2021

  Spero Therapeutics, Inc. today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2021

  8/31/2021

  Spero Therapeutics, Inc. announced that on August 31, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 98,300 shares of its common stock to 7 new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update

  8/5/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in areas of high unmet need, involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the second quarter ended June 30, 2021, and provided a business update.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 30, 2021

  7/30/2021

  Spero Therapeutics, Inc. announced that on July 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,600 shares of its common stock to ten new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

  7/29/2021

  Spero Therapeutics, Inc. announced that it will host a conference call and live audio webcast on August 5, 2021, at 4:30 p.m. ET to report its second quarter 2021 financial results and provide an update on its business and pipeline.

• Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

  7/7/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference,

• Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories

  7/5/2021

  Everest Medicines announced that Spero Therapeutics, Inc., a licensing partner of Everest Medicines, entered into a regional licensing agreement with Pfizer Inc. for SPR206, Spero's intravenously -administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant Gram-negative infections in the hospital setting.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2021

  7/2/2021

  Spero Therapeutics, Inc. announced that on June 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 85,650 shares of its common stock to nine new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

  6/30/2021

  Spero Therapeutics, Inc announced that Pfizer Inc. has made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs.

• 

  Clinical Catch-Up: June 14-18

  6/21/2021

  It was another busy week of clinical trial announcements. Here’s a look.

• Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206

  6/15/2021

  Spero Therapeutics, Inc.  today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate.

• Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206

  5/17/2021

  The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206

• Spero Therapeutics to Participate at the Berenberg Conference USA

  5/13/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA,

• Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update

  5/6/2021

  Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced financial results for the first quarter ended March 31, 2021 and provided a business update.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 30, 2021

  4/30/2021

  Spero Therapeutics, Inc. announced that on April 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 28,600 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

• Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

  4/29/2021

  Spero Therapeutics, Inc. announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 31, 2021

  3/31/2021

  Spero Therapeutics, Inc. announced that on March 31, 2021 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,050 shares of its common stock to three new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update

  3/11/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2020 and provided a business update.

• Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

  3/3/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021